CEO Letter Reveals Imminent Revenue, Scaled Output, and Strategic Milestones
June 3, 2025 – WallStreet-PR.com — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a longtime trailblazer in spider silk development, just dropped one of its most consequential shareholder updates to date. The letter from CEO Kim Thompson outlines a confluence of game-changing scientific progress, industrial-scale readiness, and pending commercial engagements with global brands.
For investors who’ve tracked KBLB’s evolution from a gene-editing concept to an emerging advanced materials supplier, this update marks a decisive pivot from lab to commercial markts.
Global Brands Lined Up for First Shipments
Three globally recognized companies spanning luxury fashion, high-performance sportswear, and athletic gear are now in commercial engagement with Kraig Labs and preparing to receive initial shipments of its recombinant spider silk.
According to the shareholder letter:
- A leading luxury fashion brand has accepted a quote.
- A premier performance sportswear company has allocated budget for spider silk procurement.
- A top-five global athletic equipment manufacturer is preparing to integrate silk into flagship products.
Shipments are expected to commence in the second half of 2025, confirming what many bulls hoped: Kraig’s technology is not only functional it’s market-ready.
Next-Gen “Double Hybrid” Silk System On Deck
In one of the more overlooked, yet potentially seismic, developments: Kraig announced its double hybrid silkworm strain remains on track for 2025 deployment.
The anticipated outcome? A 25%+ increase in monthly production capacity, laying the foundation for scalable, commercial-grade volumes.
Production Resilience Validated
Kraig’s current BAM-1 hybrid strain has already proven itself in the field, matching the disease resistance and durability of China’s commercial silk standard. This resilience has allowed the company to navigate the same environmental pressures such as heavy rains that disrupt even traditional silk producers.
Commercial Inventory Now Stockpiling
The Company has confirmed that hundreds of kilograms of spider silk cocoon have been stockpiled for processing. This material will now be accounted for in Work-in-Progress (WIP) inventory, signaling the company’s full transition from R&D-mode into operational-scale manufacturing.
A Year of Revolution
According to Thompson, the past 14 months represent nothing short of a revolution in spider silk production:
“We are 100% focused on the production of spider silk for commercial delivery. Over the last year, we’ve been able to move faster to deliver on that commitment,” Thompson stated.
Why This Matters for Investors
This update marks a turning point in KBLB’s trajectory—from speculative biotech to commercial materials science company. With:
- Proven industrial strains,
- Commercial partnerships in motion,
- Inventory scale-up underway, and
- The next-gen system on the horizon,
Kraig is now poised to generate real revenue from its proprietary spider silk technology.
The market will be watching closely in the months ahead for confirmation of deliveries and revenue recognition.
For analyst reports or investor relations inquiries, reach out to [email protected] ([email protected]).
Disclaimer: This article reflects the views of Wallstreet-pr.com editors and is not investment advice. Investors should conduct their own research and consult financial professionals before making investment decisions.
All information, opinions, analyses, technical analysis, trading price targets, and support and resistance interpretations presented in this publication represent the author’s or as stated third party’s personal views and are fully protected under the First Amendment of the United States Constitution. The content provided herein is intended solely as editorial opinion, general market commentary, or educational material, and should never be construed as financial or investment advice. This publication does not constitute a solicitation or recommendation to buy or sell securities, commodities, or any other financial instruments. Readers are strongly advised to conduct their own independent research or seek professional advice before making any investment decisions. For additional information regarding First Amendment protections for financial newsletters and commentary, please refer to Lowe v. SEC, 472 U.S. 181 (1985): https://supreme.justia.com/cases/federal/us/472/181/.”
About Wall Street PR
Wall Street PR, a leading press release provider, has proudly served the financial community for over 20 years, providing timely and insightful market news. Our expert team delivers customized press releases that enhance visibility for businesses and investors. With an extensive distribution network and a commitment to accuracy and strategic communications, Wall Street PR ensures that your message reaches the right audience with maximum impact. When Wall Street PR writes about a company, investors pay attention.
[email protected]
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made based on management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward-looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Wall street pr has been compensated for the publication of news coverage for Kraig labs., Please read the full disclosure below.
